financetom
Business
financetom
/
Business
/
Solventum Reports Early Results of Tender Offers
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Solventum Reports Early Results of Tender Offers
Sep 8, 2025 7:33 AM

10:08 AM EDT, 09/08/2025 (MT Newswires) -- Solventum ( SOLV ) reported Monday early results of its tender offers for several senior notes for an aggregate purchase price of $2 billion in cash.

The company said about $937.5 million of its 5.45% senior notes due 2027, $1.3 billion of its 5.4% senior notes due 2029, $457.6 million of its 6% senior notes due 2064, and $858.8 million of its 5.9% senior notes due 2054 were validly tendered as of the early tender date of 5 pm ET on Friday, the company said.

Solventum ( SOLV ) said it upsized the tender offer's aggregate cap to $2 billion from $1.75 billion.

Shares were up 1.5% in recent early trading.

Price: 73.80, Change: +1.08, Percent Change: +1.49

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Google agrees $36 million fine for anti-competitive deals with Australia telcos
Google agrees $36 million fine for anti-competitive deals with Australia telcos
Aug 17, 2025
SYDNEY, Aug 18 (Reuters) - Google agreed on Monday to pay a A$55 million ($35.8 million) fine in Australia after the consumer watchdog found it had hurt competition by paying the country's two largest telcos to pre-install its search application on Android phones, excluding rival search engines. The fine extends a bumpy period for the Alphabet-owned internet giant in Australia,...
Healthcare Services Q2 Loss Widens, Revenue Rises
Healthcare Services Q2 Loss Widens, Revenue Rises
Jul 23, 2025
07:34 AM EDT, 07/23/2025 (MT Newswires) -- Healthcare Services Group ( HCSG ) reported a Q2 loss Wednesday of $0.44 per diluted share, wider than a loss of $0.02 a year earlier. Two analysts surveyed by FactSet expected earnings of $0.21 per share. Revenue for the three months ended June 30 was $458.5 million, up from $426.3 million last year....
Castle Biosciences Says FDA Granted Breakthrough Device Designation to Skin Cancer Test; Shares Up Pre-Bell
Castle Biosciences Says FDA Granted Breakthrough Device Designation to Skin Cancer Test; Shares Up Pre-Bell
Jul 23, 2025
07:31 AM EDT, 07/23/2025 (MT Newswires) -- Castle Biosciences ( CSTL ) said Wednesday the US Food and Drug Administration has granted breakthrough device designation for the company's DecisionDx-Melanoma test. DecisionDx-Melanoma is a gene expression profile test that provides results to guide risk-aligned management decisions for patients diagnosed with stage I to III cutaneous melanoma, a type of skin cancer....
Abivax Stock Skyrockets On Strong Data From Inflammatory Bowel Disorder Study
Abivax Stock Skyrockets On Strong Data From Inflammatory Bowel Disorder Study
Jul 23, 2025
Abivax SA ( ABVX ) stock is skyrocketing on Wednesday after the clinical-stage biotechnology company announced overwhelmingly positive topline results from its Phase 3 ABTECT-1 (Study 105) and ABTECT-2 (Study 106) 8-week induction trials for oral obefazimod (ABX464) in adult patients with moderately to severely active ulcerative colitis. The Paris-based company achieved a significant breakthrough with its experimental treatment, which...
Copyright 2023-2026 - www.financetom.com All Rights Reserved